Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study to evaluate efficacy and safety of PD-1 inhibitors plus chemotherapy (albumin paclitaxel with S1) as first line in patients with advanced biliary tract cancers

Next Previous
Search
Trial Profile

A retrospective study to evaluate efficacy and safety of PD-1 inhibitors plus chemotherapy (albumin paclitaxel with S1) as first line in patients with advanced biliary tract cancers

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Sintilimab (Primary) ; Toripalimab (Primary) ; Gimeracil/oteracil/tegafur; Paclitaxel
  • Indications Biliary cancer; Cholangiocarcinoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 16 Jun 2020 New trial record
    • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top